Nolato's Nomination Committee will nominate Tomas Blomquist as a new member of the Board ahead of the company's 2021 AGM. Tomas Blomquist, born 1970, has in-depth knowledge and wide-ranging experience within the field of health care, with a focus on diagnostics and medical technology, and over the past two decades has held a number of senior management positions in both global and regional companies. Since 2019 Tomas has been President and CEO of Biotage, which provides solutions for customer workflows in pharmaceutical research and manufacturing, as well as analytical testing and water and environmental analysis. He has previously held senior management positions at Abbott, Roche, Johnson & Johnson and Analyticon Biotechnologies.
The Nomination Committee will also propose the re-election of the current Board of Directors: Fredrik Arp, Sven Boström-Svensson, Lovisa Hamrin, Åsa Hedin, Erik Lynge-Jorlén, Lars-Åke Rydh and Jenny Sjödahl, and the re-election of Fredrik Arp as Chairman of the Board.
Nolato's 2021 AGM will be held on Tuesday 4 May.
Nolato is a Swedish group with operations in Europe, Asia and North America. We develop and manufacture products in polymer materials such as plastic, silicone and TPE for leading customers within medical technology, pharmaceuticals, consumer electronics, telecom, automotive, hygiene and other selected industrial sectors. Nolato's shares are listed on Nasdaq Stockholm in the Large Cap segment, where they are included in the Industrials sector.
This information was distributed by Cision http://www.cisionwire.se/